New pill aims to outsmart resistant cancers
NCT ID NCT01273168
Summary
This early-stage trial tested a new drug called Z-Endoxifen in adults whose hormone-linked cancers had stopped responding to standard treatments. The study aimed to find a safe daily dose and see if the drug could slow or stop tumor growth. It involved 40 people with specific cancers like breast, gynecologic, or desmoid tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GYNECOLOGIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.